Sunday, April 09, 2017 5:32:48 PM
Would you take a drug that is "safe to a large degree", but may cause long term side effects unless you were desperate and had little quality of life left?
There was no possibility the 2-73 patients were "depressed". It was a 3rd party trial paid for and overseen by the Aussie government."
So did they have so little confidence in their drug that they were only willing to test it on someone else's dime?
On depression vs Alzheimer's:
"Similar symptoms
Some of the symptoms common to both Alzheimer's and depression include:
Loss of interest in once-enjoyable activities and hobbies
Social withdrawal
Memory problems
Sleeping too much or too little
Impaired concentration
With so much overlap in symptoms, it can be hard to tell the difference between the two disorders, especially since they often occur together. A thorough physical exam and psychological evaluation can be helpful in making a diagnosis.
But, many people with more advanced Alzheimer's disease may not be able to express how they feel."
"Early Alzheimer's disease and depression share many symptoms, so it can be hard — even for doctors — to distinguish between the disorders. Plus, many people with Alzheimer's disease also are depressed."
http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048362
What is the primary outcome measure in Anavex's current trial? Post it here when you find it.
There was no possibility the 2-73 patients were "depressed". It was a 3rd party trial paid for and overseen by the Aussie government."
So did they have so little confidence in their drug that they were only willing to test it on someone else's dime?
On depression vs Alzheimer's:
"Similar symptoms
Some of the symptoms common to both Alzheimer's and depression include:
Loss of interest in once-enjoyable activities and hobbies
Social withdrawal
Memory problems
Sleeping too much or too little
Impaired concentration
With so much overlap in symptoms, it can be hard to tell the difference between the two disorders, especially since they often occur together. A thorough physical exam and psychological evaluation can be helpful in making a diagnosis.
But, many people with more advanced Alzheimer's disease may not be able to express how they feel."
"Early Alzheimer's disease and depression share many symptoms, so it can be hard — even for doctors — to distinguish between the disorders. Plus, many people with Alzheimer's disease also are depressed."
http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048362
What is the primary outcome measure in Anavex's current trial? Post it here when you find it.
Recent TAOX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:21:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/02/2026 09:32:45 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/02/2026 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:23:07 PM
- TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation • PR Newswire (US) • 11/18/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/12/2025 09:10:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/07/2025 09:41:16 PM
- TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds • PR Newswire (US) • 11/04/2025 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/24/2025 08:12:47 PM
- TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency • PR Newswire (US) • 10/20/2025 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2025 09:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 10:12:21 AM
- TAO Synergies Announces $11 Million Private Placement • PR Newswire (US) • 10/13/2025 09:09:00 PM
- TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO) • PR Newswire (US) • 09/22/2025 01:15:00 PM
- TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event • PR Newswire (US) • 09/08/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2025 09:00:44 PM
- TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy • PR Newswire (US) • 08/26/2025 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2025 08:51:57 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2025 08:50:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 08:19:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 09:17:38 PM
